Seminars in Oncology
Volume 30, Issue 5 , Pages 635-648 , October 2003

Genome-wide gene expression analysis of prostate carcinoma

  • William L Gerald

      Affiliations

    • Corresponding Author InformationAddress reprint requests to William L. Gerald, MD, PhD, Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    • Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

References 

  1. Ladanyi M, Chan WC, Triche TJ, et al.  Expression profiling of human tumors (The end of surgical pathology?). J Mol Diagn. 2001;3:92–97
  2. Lakhani SR, Ashworth A. Microarray and histopathological analysis of tumours (The future and the past?). Nature Rev Cancer. 2001;1:151–157
  3. Bertucci F, Houlgatte R, Nguyen C, et al.  Gene expression profiling of cancer by use of DNA arrays (How far from the clinic?). Lancet Oncol. 2001;2:674–682
  4. Alizadeh AA, Ross DT, Perou CM, et al.  Towards a novel classification of human malignancies based on gene expression patterns. J Pathol. 2001;195:41–52
  5. Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. J Clin Oncol. 2002;20:1932–1941
  6. Barry M. Prostate specific antigen testing for early diagnosis of prostate cancer. N Engl J Med. 2001;344:1373–1377
  7. Oesterling J, Fuks Z, Lee C, et al.  Cancer of the prostate. In:  Devita VT,  Hellman S,  Rosenberg SA editor. Cancer (Principles and Practice of Oncology). (ed 5). Philadelphia, PA: Lippincott-Raven; 1997;p. 186–1322
  8. The Chipping Forecast. Nature Genet. 1999;21(suppl):1–61
  9. Gleason DF. Histologic grading of prostate cancer (A perspective). Hum Pathol. 1992;23:273–279
  10. Bostwick DG, Shan A, Qian J, et al.  Independent origin of multiple foci of prostatic intraepithelial neoplasia (Comparison with matched foci of prostate carcinoma). Cancer. 1998;83:1995–2002
  11. Macintosh CA, Stower M, Reid N, et al.  Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res. 1998;58:223–228
  12. Liu AY, Nelson P, van den Engh G, et al.  Human prostate epithelial cell-type cDNA libraries and prostate expression patterns. Prostate. 2002;50:92–103
  13. Quackenbush J. Computational analysis of microarray data. Nat Rev Genet. 2001;2:418–427
  14. Wheeler DL, Chappey C, Lash AE, et al.  Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2000;28:10–14
  15. Nelson PS, Pritchard C, Abbott D, et al.  The human (PEDB) and mouse (mPEDB) prostate expression databases. Nucleic Acids Res. 2002;30:218–220
  16. Waghray A, Schober M, Feroze F, et al.  Identification of differentially expressed genes by serial analysis of gene expression in human prostate cancer. Cancer Res. 2001;61:4283–4286
  17. LaTulippe E, Satagopan J, Smith A, et al.  Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 2002;62:4499–4506
  18. Dhanasekaran S, Barrette T, Ghosh D. Delineation of prognostic biomarkers in prostate cancer. Nature. 2001;412:822–826
  19. Luo J, Duggan D, Chen Y, et al.  Human prostate cancer and benign prostatic hyperplasia (Molecular dissection by gene expression profiling). Cancer Res. 2001;61:4683–4688
  20. Magee J, Araki T, Patil S, et al.  Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 2001;61:5692–5696
  21. Welsh J, Sapinoso L, Su A, et al.  Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 2001;61:5974–5978
  22. Luo J-H, Yu Y, Cieply K, et al.  Gene expression analysis of prostate cancers. Mol Carcino. 2002;33:25–35
  23. Singh D, Febbo P, Ross K, et al.  Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 2002;1:203–209
  24. Stamey T, Warrington J, Caldwell M, et al.  Molecular genetic profiling of Gleason grad4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol. 2001;166:2171–2177
  25. Xu L, Su Y, Labiche R, et al.  Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. Int J Cancer. 2001;92:322–328
  26. Nelson P, Han D, Rochon Y, et al.  Comprehensive analyses of prostate gene expression (Convergence of expressed sequence tag databases, transcript profiling and proteomics). Electrophoresis. 2000;21:1823–1831
  27. Vaarala M, Porvari K, Kyllogen A, et al.  Differentially expressed genes in two LNCaP prostate cancer cell lines reflecting changes during prostate cancer progression. Lab Invest. 2000;80:1259–1268
  28. DePrimo S, Diehn M, Nelson J, et al.  Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol. 2002;3:0032.1–0032.12
  29. Nelson P, Clegg N, Arnold H, et al.  The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA. 2002;99:11890–11895
  30. Bubendorf L, Kolmer M, Kononen J, et al.  Hormone therapy failure is human prostate cancer (Analysis by complementary DNA and tissue microarrays). J Natl Cancer Inst. 1999;91:1758–1764
  31. Mousses S, Wagner U, Chen Y, et al.  Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene. 2001;20:6718–6723
  32. Amler L, Agus D, LeDuc C, et al.  Deregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R. Cancer Res. 2000;60:6134–6141
  33. Holzberlein J, LaTulippe E, Satagopan J, et al: Gene expression alterations associated with androgen ablation therapy of human prostate carcinoma. (in revision)
  34. Chugh A, Ray A, Gupta J. Squalene monooxygenase as hypocholesterolemic drug target revisited. Prog Lipid Res. 2003;42:37–50
  35. Steck P, Pershouse M, Jasser S, et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356–362

☆ Supported in part by National Institutes of Health Grant No. U01 CA84999.

PII: S0093-7754(03)00349-X

doi: 10.1016/S0093-7754(03)00349-X

Seminars in Oncology
Volume 30, Issue 5 , Pages 635-648 , October 2003

Article Tools

* Image Usage & Resolution